Ombrabulin (AVE8062)

DRUG10 trials

Sponsors

Sanofi

Conditions

Advanced Solid TumorsNeoplasmsNeoplasms, MalignantNon-small Cell Lung CancerOvarian Cancer RecurrentSarcomaSolid Tumor

Phase 1

AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor

CompletedNCT00719524

SanofiNeoplasms

Start: 2008-07-31End: 2013-02-28Updated: 2013-03-11

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid Tumors

CompletedNCT00968916

SanofiSolid Tumor

Start: 2009-09-30End: 2011-08-31Updated: 2014-09-19

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors

CompletedNCT01021150

SanofiNeoplasms, Malignant

Start: 2010-03-31End: 2011-05-31Target: 12Updated: 2011-06-13

A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor

CompletedNCT01063946

SanofiNeoplasms, Malignant

Start: 2010-01-31End: 2011-09-30Updated: 2011-12-21

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors

CompletedNCT01095302

SanofiNeoplasms, Malignant

Start: 2010-05-31End: 2011-12-31Updated: 2013-10-16

Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors

CompletedNCT01193595

SanofiNeoplasms, Malignant

Start: 2010-09-30End: 2014-10-31Updated: 2014-12-03

A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors

CompletedNCT01293630

SanofiAdvanced Solid Tumors

Start: 2011-01-31End: 2013-10-31Updated: 2015-10-30

Phase 2

Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer

CompletedNCT01263886

SanofiNon-small Cell Lung Cancer

Start: 2011-02-28End: 2012-10-31Updated: 2015-12-21

Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel

CompletedNCT01332656

SanofiOvarian Cancer Recurrent

Start: 2011-05-31End: 2014-07-31Updated: 2015-12-21

Phase 3

A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies

CompletedNCT00699517

Start: 2008-06-30End: 2013-04-30Updated: 2015-12-21

Related Papers

Phase I study of ombrabulin in combination with paclitaxel and carboplatin in Japanese patients with advanced solid tumors.

2024-04-012 citations

Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors

Japanese Journal of Clinical Oncology2018-02-099 citations

Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.

2015-04-0850 citations

An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors.

2014-01-308 citations